http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2741570-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8157d4945776664f631f7841cfe5841b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 |
| filingDate | 2019-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_defca3b4f0ba49c3a16df99c9170f934 |
| publicationDate | 2021-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2741570-C1 |
| titleOfInvention | Gene-therapeutic dna-vector based on gene-therapeutic dna-vector gdtt1_8nas12, carrying target gene selected from group of ifnb1, ifna14, ifna2, il12a, il12b genes to increase level of expression of these target genes, method for production and use thereof, strain escherichia coli jm110-nas/gdtt1_8nas12-ifnb1, or escherichia coli jm110-nas/gdtt1_8nas12-ifna14, or escherichia coli jm110-nas/gdtt1_8nas12-ifna2, or escherichia coli jm110-nas/gdtt1_8nas12-il12a, or escherichia coli jm110-nas/gdtt1_8nas12-il12b, carrying gene-therapeutic dna vector, method for production thereof, method for industrial production of gene-therapeutic dna vector |
| abstract | FIELD: biotechnology; medicine; agriculture.SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Gene-therapeutic DNA vector based on a genotyping DNA vector GDTT1.8NAS12, wherein the gene-therapeutic DNA vector GDTT1.8NAS12-IFNB1 contains a coding portion of the desired IFNB1 gene cloned into the genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 1, gene-therapeutical DNA vector GDTT1.8NAS12-IFNA14 contains a coding part of the target IFNA14 gene cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 2, gene-therapeutic DNA vector GDTT1.8NAS12-IFNA2 contains a coding part of the target IFNA2 gene cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 3, gene-therapeutic DNA vector GDTT1.8NAS12-IL12A contains a coding part of the target gene IL12A, cloned into a genotyping DNA vector GDTT1.8NAS12, with the nucleotide sequence SEQ ID No. 4, gene-therapeutic DNA vector GDTT1.8NAS12-IL12B contains a coding part of the target gene IL12B, cloned into a genotyping DNA-vector GDTT1.8NAS12, with a nucleotide sequence SEQ ID No.5.EFFECT: treating the diseases characterized by congenital and adaptive immunity disorders for the therapy of autoimmune, oncological, viral diseases associated with immune system imbalance, for immunomodulation including in anticancer vaccination as a gene therapeutic adjuvant.16 cl, 17 dwg, 23 ex |
| priorityDate | 2019-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 230.